Go to the list of all blogs
Rick Johnson's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
Why Is AN2 Therapeutics (ANTX) Stock Up +22.70% Today?

Why Is AN2 Therapeutics (ANTX) Stock Up +22.70% Today?

Key Takeaways

  • ANTX jumped 22.70% to $5.19, a gain of $0.96, extending an already powerful 2026 advance.
  • The primary driver was renewed investor focus on the company's Chagas disease program after AN2 Therapeutics detailed positive enabling data supporting advancement of its oral candidate AN2-502998 into a Phase 2 study.
  • Secondary support came from a sharp technical rebound: the shares had fallen in five of the prior six sessions and were trading below their 50-day moving average before Wednesday's gap higher.
  • The move was company-specific rather than sector-driven, with no macro or peer catalyst of comparable size visible during the session.
  • News Significance Score: 53/100 — Moderate clinical news paired with a price swing roughly seven times the stock's typical daily move.
  • Traders are watching for confirmation of Phase 2 enrollment timing across the company's three clinical programs and for the durability of Wednesday's volume.
  • Investors can review Price Targets, Earnings history and Forecast pages for deeper detail on the name.
  • Explore Trending AI Robots to see which automated strategies are performing best in the current market.

Session Overview

AN2 Therapeutics, Inc. (ANTX) is a Menlo Park, California–based clinical-stage biopharmaceutical company with no approved products and no product revenue. It develops small-molecule therapeutics from a boron chemistry platform, with programs in polycythemia vera, M. abscessus lung disease and chronic Chagas disease. On Wednesday the stock rose 22.70%, trading at $5.19 by late morning, against a prior session close of $4.23 — a gain of $0.96. The advance was unambiguously to the upside, with shares gapping higher at the open and reaching an intraday high near $5.28. Markets attributed the move to fresh attention on the company's Chagas program and the clinical timeline behind its lead candidates.

Chagas Data Refocuses Attention on the Pipeline

The catalyst was a company release issued before the opening bell describing positive results from two studies of AN2-502998, an oral CPSF3 inhibitor being developed as a potential cure for chronic Chagas disease. In a 28-day study in nonhuman primates with naturally acquired Trypanosoma cruzi infection, treatment produced parasite elimination in 100% of animals at exposures judged attainable in humans, and the effect was sustained through four months after dosing ended. A Phase 1 first-in-human study showed the compound was generally well tolerated at exposure levels consistent with those efficacy thresholds, with no dose-limiting toxicities.

Those findings matter because they sit at the center of the investment case. Chagas disease affects an estimated 10 million people globally, including roughly 300,000 in the United States, and there is no FDA-approved therapy for adults. Management has said it intends to initiate a Phase 2 proof-of-concept study in chronic Chagas disease late this year, in collaboration with the nonprofit Drugs for Neglected Diseases initiative, and the program would be eligible for an FDA Tropical Disease Priority Review Voucher if approved. For a company with a market capitalization of roughly $200 million and a cash position intended to fund operations into 2029, a credible step toward human efficacy data is a material re-rating event — and the stock's 2026 performance reflects that: shares remain up several hundred percent year to date.

A Rebound From a Sharp Pullback

The rally also had a clear technical component. ANTX had drifted lower through the first half of November, sliding from an intraday high of $4.90 in late October to $4.23 on Tuesday, a decline of roughly 14%. The stock had closed lower in five of the previous six sessions and sat below its 50-day moving average, which had been hovering near $4.55. Wednesday's advance cleared that level decisively, along with the 200-day average near $4.26 and the prior swing high, leaving the September highs around $6 as the next meaningful reference point. Pullbacks of that kind in thinly traded clinical-stage names are frequently followed by sharp, news-assisted reversals.

Market Context and Trading Activity

Volume confirmed the move. Roughly 74,000 shares changed hands in the first 70 minutes of trading — a pace of about 1.5 times the 50-day average daily volume of approximately 272,000 shares — suggesting genuine institutional and retail participation rather than a single thin print. The action was almost entirely idiosyncratic: there was no comparable swing among large-cap biotechnology peers, and the gain was not tied to any broad index or macro release. In practical terms, the tape reflected a single company's clinical narrative being repriced, amplified by a float of only about 22.5 million shares, which magnifies order-flow impact. Wednesday's range of roughly $4.23 to $5.28 was among the widest of the past two months.

News Significance Score

The score runs from 0 to 100, where 0 means no meaningful news and a price move that is normal for the stock, and 100 means transformative news accompanied by an extreme, rare move. ANTX earns 53 out of 100.

The verified news was moderate in weight: positive animal efficacy and clean early-stage safety data that de-risk a Phase 2 step, but not human efficacy, approval or a partnership of transformative scale — and the underlying data package had been previously disclosed as part of the program's progression. The price behavior was the stronger component. Today's 22.70% advance was about 6.8 times the stock's average absolute daily move of 3.35% over the past 60 sessions, and no session in that window produced a larger absolute change, as the biggest prior swing was 17.1%. Strong news and an unusually large move combine into a mid-range score.

What Comes Next for ANTX

Attention now shifts to execution. Investors will look for confirmation that the Phase 2 Chagas proof-of-concept study begins on the promised late-2026 timeline, alongside progress in the polycythemia vera Phase 2 program, where early safety data are expected in the first quarter of 2027, and the investigator-initiated M. abscessus trial. Earnings reports will remain largely a cash-runway story rather than a revenue story; the company last reported a third-quarter net loss and reiterated funding into 2029. Analyst coverage is thin, with a small group of analysts carrying a consensus price target well above current levels — a signal of perceived upside that also raises the bar for disappointment. Key risks include the well-documented gap between animal models and human outcomes, regulatory and enrollment delays, dilution risk as programs expand, and the sensitivity of a low-float, pre-revenue equity to sentiment shifts.

Trending AI Robots

Tickeron maintains hundreds of AI trading bots that cover thousands of tickers, but only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. Strategies differ widely by approach, timeframe, performance metrics and the specific symbols they trade, so the lineup changes as market conditions evolve. Reviewing this page can help traders see which automated approaches are working right now before committing capital. Investors curious about systematic strategies may find it a useful starting point for further research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ANTX

ANTX's RSI Oscillator ascends from oversold territory

The RSI Indicator for ANTX moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 19 similar instances when the indicator left oversold territory. In 16 of the 19 cases the stock moved higher. This puts the odds of a move higher at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on ANTX as a result. In 60 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for ANTX just turned positive on October 27, 2026. Looking at past instances where ANTX's MACD turned positive, the stock continued to rise in 25 of 30 cases over the following month. The odds of a continued upward trend are 83%.

ANTX moved above its 50-day moving average on November 18, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +11.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANTX advanced for three days, in 201 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 46 cases where ANTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

ANTX broke above its upper Bollinger Band on November 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ANTX entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.988) is normal, around the industry mean (3.592). P/E Ratio (-3.810) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ANTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -4%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
Managed Health Care
Address
1300 El Camino Real
Phone
+1 650 331-9090
Employees
21
Web
https://www.an2therapeutics.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
CBRS fell -6.07% to $97.86 in the opening minutes of Wednesday's regular session, down from Tuesday's close of $104.18 — the move occurred during market hours, not premarket or after-hours. No verified news or fundamental catalyst found: no new filing, contract, or analyst action explains the drop, which is likely continued give-back from the post-earnings pop and the stock's habitual volatility — CBRS has averaged a ±4.5% daily swing over the past 60 sessions, and 17 of those sessions moved as much or more.
NVIDIA reported revenue of $115.84 billion for the third quarter of fiscal 2027, up 103% year over year and ahead of both company guidance and consensus estimates. Non-GAAP earnings per share (EPS, a measure of profit per outstanding share) came in at $2.68 , beating the roughly $2.47 analysts had expected.